|
시장보고서
상품코드
2051214
인플루엔자 백신 시장 : 백신 유형별, 가수별, 투여 경로별, 연령층별, 기술별, 유통 채널별, 지역별Influenza Vaccines Market, By Vaccine Type, By Valency, By Route of Administration, By Age Group, By Technology, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
인플루엔자 백신 시장은 2026년에 95억 8,000만 달러로 추정되며, 2033년까지 158억 9,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 7.5%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 95억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 7.50% | 2033년 시장 규모 예측 : | 158억 9,000만 달러 |
독감 백신은 수십년동안 건강 관리의 중요한 요소로 자리 잡았습니다. 독감 바이러스는 주기적으로 변이 및 진화하는 능력을 가지고 있기 때문에 매년 최신 백신을 개발해야 합니다. 백신은 이러한 변화하는 바이러스에 대한 인체의 면역반응을 강화하는 역할을 합니다. 백신은 특정 지역에서 다음 독감 시즌에 유행할 가능성이 가장 높은 것으로 감시 및 기타 과학적 연구를 통해 확인된 3유형 또는 4유형의 균주(특정 독감 시즌에 사용되는 백신의 유형에 따라 다름)에 대한 면역력을 부여하도록 설계되어 있습니다. 하도록 설계되어 있습니다. 세계 독감 백신 시장은 계절성 백신 접종에 대한 인식 증가, 신기술 도입, 의료기관의 백신 접종 가이드라인 확대, 전 세계 정부 지원 증가로 지난 몇 년 동안 꾸준한 성장세를 보이고 있습니다.
시장 역학
세계 독감 백신 시장의 성장은 독감 유행 확대, 국제보건기구의 백신 접종 가이드라인 채택 확대, 백신 접종에 대한 인식 제고, 신제품 출시, 재조합 기술을 이용한 백신 선호도 증가, 주요 기업의 사업 진출 지역 확대 등 다양한 요인에 의해 주도되고 있습니다. 에 의해 견인되고 있습니다. 그러나 4가 독감 백신 개발에 따른 높은 연구개발비용, 신규 백신 승인에 대한 엄격한 규제 가이드라인, 독감 바이러스 균주의 항원 변이로 인한 백신 내성 발생 등으로 인해 시장 성장에는 어려움이 따릅니다. 시장 참여자들은 의료 인프라의 개선과 가처분 소득 증가로 인해 신흥국에서 비즈니스 기회를 발견하고 있습니다. 또한, 각 제조업체들은 여러 독감 균주에 대해 지속적인 예방 효과를 가진 범용형 독감 백신 개발에도 힘쓰고 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계 독감 백신 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계 독감 백신 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 독감 백신 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 인플루엔자 백신 시장 : 백신 유형별, 2021년-2033년
제5장 세계의 인플루엔자 백신 시장 : 가수별, 2021년-2033년
제6장 세계의 인플루엔자 백신 시장 : 투여 경로별, 2021년-2033년
제7장 세계의 인플루엔자 백신 시장 : 연령층별, 2021년-2033년
제8장 세계의 인플루엔자 백신 시장 : 기술별, 2021년-2033년
제9장 세계의 인플루엔자 백신 시장 : 유통 채널별, 2021년-2033년
제10장 세계의 인플루엔자 백신 시장 : 지역별, 2021년-2033년
제11장 경쟁 구도
제12장 애널리스트의 견해
제13장 참고 문헌 및 조사 방법
LSH 26.06.17Influenza Vaccines Market is estimated to be valued at USD 9.58 Bn in 2026 and is expected to reach USD 15.89 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9.58 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.50% | 2033 Value Projection: | USD 15.89 Bn |
Influenza vaccines have been an important element of preventive healthcare for decades. The influenza viruses have the ability to mutate and evolve regularly, necessitating the development of updated vaccines each year. The vaccines work to boost the body's immune response to these changing viruses. They are designed to immunize against the three or four strains (depending on the vaccine type used for a particular flu season) that surveillance and other scientific studies have determined are most likely to be in circulation for the upcoming flu season in any given region. The global influenza vaccines market has witnessed steady growth over the past few years due to the growing awareness about seasonal vaccination, introduction of novel technologies, expansion of vaccination guidelines by healthcare organizations, and rising government support worldwide.
Market Dynamics
The global influenza vaccines market growth is driven by various factors such as the increasing prevalence of influenza, growing adoption of vaccination guidelines set by international health organizations, rising awareness about vaccination, new product launches, growing preference for recombinant technology vaccines, and expansion in geographical reach of major players. However, the market growth can be challenging due to high R&D costs involved for development of quadrivalent influenza vaccines, stringent regulatory guidelines for approval of new vaccines and vaccine resistance arising due to antigenic drift of influenza virus strains. The market players see opportunities in emerging countries owing to improving healthcare infrastructure and rising disposable incomes. Manufacturers are also working on the development of universal influenza vaccine with durable protection against multiple flu strains.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global influenza vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen Inc., Moderna Inc., Biocryst Pharmaceuticals Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, Solaris Vaccines, Pfizer, CSL, Daiichi Sankyo, Bharat Biotech, and Sinovac Biotech.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global influenza vaccines market.
Market Segmentation
- Vaccine Type Insights (Revenue, USD Bn, 2026 - 2033)
- Inactivated
- Live Attenuated
- Valency Insights (Revenue, USD Bn, 2026 - 2033)
- Quadrivalent
- Trivalent
- Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
- Injection
- Nasal Spray
- Age Group Insights (Revenue, USD Bn, 2026 - 2033)
- Pediatrics
- Adults
- Technology Insights (Revenue, USD Bn, 2026 - 2033)
- Egg-Based Flu Vaccines
- Cell Culture-Based Flu Vaccines
- Recombinant Flu Vaccines
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Public
- Private
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen Inc.
- Moderna Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Valency
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Technology
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Developments
- Industry Trends
- Regulatory Scenario
- Recent Product Approval/Launches
- PEST Analysis
- Porter's Analysis
4. Global Influenza Vaccines Market, By Vaccine Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Inactivated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Live Attenuated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Influenza Vaccines Market, By Valency, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Quadrivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Trivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Influenza Vaccines Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Influenza Vaccines Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Influenza Vaccines Market, By Technology, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Egg-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cell Culture-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Recombinant Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Influenza Vaccines Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Influenza Vaccines Market, By Region, 2021 - 2033 (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033(%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Region/Country, 2021 - 2033 (USD Bn)
- South Africa
- Central Africa
- North Africa
11. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- CSL Seqirus
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- FluGen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Moderna, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biocryst Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CPL Biologicals Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CureVac AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- OSIVAX
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Solaris Vaccines
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sinovac Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Solaris Vaccines
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CSL Seqirus
12. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
